Polynovo Ltd
ASX:PNV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (21.6), the stock would be worth AU$2.84 (185% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.6 | AU$1 |
0%
|
| 3-Year Average | 21.6 | AU$2.84 |
+185%
|
| 5-Year Average | 26.6 | AU$3.5 |
+252%
|
| Industry Average | 2.4 | AU$0.31 |
-69%
|
| Country Average | 1.7 | AU$0.23 |
-77%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Polynovo Ltd
ASX:PNV
|
687.4m AUD | 7.6 | 70.9 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 13.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 1.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 2.4 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 2.3 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | 0.8 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 2.1 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 5 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 1.9 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | 9.6 | -36.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Polynovo Ltd
Glance View
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
